Reliability of a newly-developed immunochromatography diagnostic kit for pandemic influenza A/H1N1pdm virus: implications for drug administration

PLoS One. 2012;7(11):e50670. doi: 10.1371/journal.pone.0050670. Epub 2012 Nov 30.

Abstract

Background: For the diagnosis of seasonal influenza, clinicians rely on point-of-care testing (POCT) using commercially available kits developed against seasonal influenza viruses. However, POCT has not yet been established for the diagnosis of pandemic influenza A virus (H1N1pdm) infection due to the low sensitivity of the existing kits for H1N1pdm.

Methodology/principal findings: An immunochromatography (IC) test kit was developed based on a monoclonal antibody against H1N1pdm, which does not cross-react with seasonal influenza A or B viruses. The efficacy of this kit (PDM-IC kit) for the diagnosis of H1N1pdm infection was compared with that of an existing kit for the detection of seasonal influenza viruses (SEA-IC kit). Nasal swabs (n = 542) were obtained from patients with flu-like syndrome at 13 clinics in Osaka, Japan during the winter of 2010/2011. Among the 542 samples, randomly selected 332 were further evaluated for viral presence by reverse transcriptase polymerase chain reaction (RT-PCR). The PDM-IC kit versus the SEA-IC kit showed higher sensitivity to and specificity for H1N1pdm, despite several inconsistencies between the two kits or between the kits and RT-PCR. Consequently, greater numbers of false-negative and false-positive cases were documented when the SEA-IC kit was employed. Significant correlation coefficients for sensitivity, specificity, and negative prediction values between the two kits were observed at individual clinics, indicating that the results could be affected by clinic-related techniques for sampling and kit handling. Importantly, many patients (especially influenza-negative cases) were prescribed anti-influenza drugs that were incongruous with their condition, largely due to physician preference for patient responses to questionnaires and patient symptomology, as opposed to actual viral presence.

Conclusions/significance: Concomitant use of SEA-IC and PDM-IC kits increased the likelihood of correct influenza diagnosis. Increasing the credibility of POCT is anticipated to decrease the inappropriate dispensing of anti-influenza drugs, thereby minimizing the emergence of drug-resistant H1N1pdm strains.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Animals
  • Antiviral Agents / administration & dosage
  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use*
  • Child
  • Child, Preschool
  • Chromatography, Affinity / methods*
  • Dogs
  • Drug Prescriptions / statistics & numerical data
  • Female
  • Humans
  • Infant
  • Infant, Newborn
  • Influenza A Virus, H1N1 Subtype / drug effects
  • Influenza A Virus, H1N1 Subtype / genetics
  • Influenza A Virus, H1N1 Subtype / isolation & purification*
  • Influenza A Virus, H1N1 Subtype / physiology*
  • Influenza, Human / diagnosis*
  • Influenza, Human / drug therapy
  • Influenza, Human / epidemiology*
  • Madin Darby Canine Kidney Cells
  • Male
  • Middle Aged
  • Pandemics*
  • Point-of-Care Systems
  • Predictive Value of Tests
  • Reproducibility of Results
  • Time Factors
  • Young Adult

Substances

  • Antiviral Agents

Grants and funding

This work was supported in part by a Grant-in-Aid for Scientific Research (B) (Overseas Academic Research) from the Japan Society for the Promotion of Science to K.I. Also, this work was partly supported by funding from Alfresa Phama Corporation to Osaka University to perform a collaborative research. The funders had no role in study design, data collection or analysis, decision to publish, or preparation of the manuscript. No additional external funding was received for this study.